Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03589482
Other study ID # 18-6091
Secondary ID 17-6226
Status Completed
Phase N/A
First received
Last updated
Start date March 1, 2019
Est. completion date August 31, 2021

Study information

Verified date August 2020
Source University Health Network, Toronto
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Mechanical ventilation can cause damage by overstretching the lungs, especially when the lungs are collapsed or edematous. Raising ventilator pressures can reduce lung collapse and this can prevent overstretching from mechanical ventilation. It remains uncertain how much pressure (PEEP - positive end-expiratory pressure) should be used on the ventilator and how to identify patients who will benefit from higher ventilator pressures vs. lower ventilator pressures. The investigators are using a unique new imaging technology, electrical impedance tomography (EIT), to study this problem and to determine the safest and most effective ventilator pressure level. The results of this study will inform future trials of higher vs. lower PEEP strategies in mechanically ventilated patients.


Description:

Patients participating in this physiological cross-over randomized trial will undergo a series of PEEP maneuvers designed to assess lung recruitability, PEEP responsiveness, and optimal PEEP. EIT imaging and esophageal manometry will be employed throughout the protocol to quantify the effect of PEEP on lung function. Patients will be randomized to be ventilated at PEEP levels supplied by the ExPRESS strategy or by the EIT hyperdistention/collapse algorithm. The biological response will be assessed by measuring serum cytokines.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date August 31, 2021
Est. primary completion date March 31, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Acute (=7 days) hypoxemia with PaO2:FiO2 ratio less than or equal to 200 mm Hg - Oral endotracheal intubation and mechanical ventilation - Bilateral airspace opacities on chest radiograph or CT Exclusion Criteria: - Contraindication to EIT electrode placement (burns, chest wall bandaging limiting electrode placement) - Contraindication to esophageal catheter placement (recent upper GI surgery, actively bleeding esophageal varices) - Respiratory failure predominantly due to cardiogenic cause or fluid overload - Ongoing hemodynamic instability (requiring 2 vasopressor agents by continuous infusion AND rising vasopressor infusion rate requirements in the previous 8 hours) - Ongoing ventilatory instability (P/F < 70 mm Hg, pH < 7.2; ventilator driving pressures, PEEP, or FiO2 increasing by more than 25% in previous 30 minutes) - Intracranial hypertension (suspected or diagnosed by medical team) - Known or suspected pneumothorax recognized within previous 72 hours - Bronchopleural fistula - Bridge to lung transplant - Recent lung transplantation (within previous 6 weeks) - Attending physician deems the transient application of high airway pressures (>40 cm H2O) to be unsafe

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Electrical Impedance Tomography
Electrical impedance tomography (EIT) is a new technique that enables real-time visualization of the distribution of ventilation at the bedside. This technique allows clinicians and investigators to immediately determine how applying higher or lower PEEP levels affect stress and strain in the lung. The investigators propose to apply this new technique to test a strategy for finding the optimal level of PEEP that prevents lung injury and improves outcomes in critically ill patients.
Other:
ExPRESS-derived PEEP level
The ExPRESS algorithm is a traditional approach to selecting PEEP based on respiratory mechanics.

Locations

Country Name City State
Canada University Health Network Toronto Ontario

Sponsors (1)

Lead Sponsor Collaborator
University Health Network, Toronto

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Intratidal ventilation heterogeneity A measure of variation in the distribution of ventilation throughout the lung as detected by electrical impedance tomography Assessed after completion of 3 hours on randomized strategy (EIT vs ExPRESS)
Secondary Difference in the optimal PEEP levels identified by several different PEEP titration strategies Compare the relative degree of agreement or disparity between PEEP levels recommended by different PEEP titration strategies Assessed immediately after completion of decremental PEEP titration procedure
Secondary Change in ratio of partial pressure of oxygen (PaO2) to inspired fraction of oxygen (FiO2) ratio following a standardized increased in PEEP Measurement of changes in oxygenation by PaO2/FiO2 ratio due to PEEP Assessed 10 minutes after step PEEP increase from 6-8 to 16-18 cm H2O
Secondary Respiratory mechanics (transpulmonary driving pressure) The swing in transpulmonary pressure during inspiration, a measure of dynamic lung stress Assessed after completing 3 hours on the randomized PEEP strategy (EIT vs ExPRESS)
See also
  Status Clinical Trial Phase
Completed NCT04384445 - Zofin (Organicell Flow) for Patients With COVID-19 Phase 1/Phase 2
Recruiting NCT05535543 - Change in the Phase III Slope of the Volumetric Capnography by Prone Positioning in Acute Respiratory Distress Syndrome
Completed NCT04695392 - Restore Resilience in Critically Ill Children N/A
Terminated NCT04972318 - Two Different Ventilatory Strategies in Acute Respiratory Distress Syndrome Due to Community-acquired Pneumonia N/A
Completed NCT04534569 - Expert Panel Statement for the Respiratory Management of COVID-19 Related Acute Respiratory Failure (C-ARF)
Completed NCT04078984 - Driving Pressure as a Predictor of Mechanical Ventilation Weaning Time on Post-ARDS Patients in Pressure Support Ventilation.
Completed NCT04451291 - Study of Decidual Stromal Cells to Treat COVID-19 Respiratory Failure N/A
Not yet recruiting NCT06254313 - The Role of Cxcr4Hi neutrOPhils in InflueNza
Not yet recruiting NCT04798716 - The Use of Exosomes for the Treatment of Acute Respiratory Distress Syndrome or Novel Coronavirus Pneumonia Caused by COVID-19 Phase 1/Phase 2
Withdrawn NCT04909879 - Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Non-COVID-19 Acute Respiratory Distress Syndrome Phase 2
Not yet recruiting NCT02881385 - Effects on Respiratory Patterns and Patient-ventilator Synchrony Using Pressure Support Ventilation N/A
Terminated NCT02867228 - Noninvasive Estimation of Work of Breathing N/A
Completed NCT02545621 - A Role for RAGE/TXNIP/Inflammasome Axis in Alveolar Macrophage Activation During ARDS (RIAMA): a Proof-of-concept Clinical Study
Completed NCT02232841 - Electrical Impedance Imaging of Patients on Mechanical Ventilation N/A
Withdrawn NCT02253667 - Palliative Use of High-flow Oxygen Nasal Cannula in End-of-life Lung Disease Patients N/A
Completed NCT01504893 - Very Low Tidal Volume vs Conventional Ventilatory Strategy for One-lung Ventilation in Thoracic Anesthesia N/A
Withdrawn NCT01927237 - Pulmonary Vascular Effects of Respiratory Rate & Carbon Dioxide N/A
Completed NCT02889770 - Dead Space Monitoring With Volumetric Capnography in ARDS Patients N/A
Completed NCT01680783 - Non-Invasive Ventilation Via a Helmet Device for Patients Respiratory Failure N/A
Completed NCT02814994 - Respiratory System Compliance Guided VT in Moderate to Severe ARDS Patients N/A